Dieter Koeberle
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
Adamina M, Warlaumont M, Berger M, Däster S, Delaloye R, Digklia A, Gloor B, Fritsch R, Koeberle D, Koessler T, Lehmann K, Müller P, Peterli R, Ris F, Steffen T, Weisshaupt C, Hübner M. Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. Cancers (Basel) 2022; 14
01.09.2022Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
01.09.2022Cancers (Basel) 2022; 14
Adamina Michel, Warlaumont Maxime, Berger Martin D, Däster Silvio, Delaloye Raphaël, Digklia Antonia, Gloor Beat, Fritsch Ralph, Koeberle Dieter, Koessler Thibaud, Lehmann Kuno, Müller Phaedra, Peterli Ralph, Ris Frédéric, Steffen Thomas, Weisshaupt Christian, Hübner Martin
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers (Basel) 2022; 14
27.04.2022Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
27.04.2022Cancers (Basel) 2022; 14
Jörger Markus, Metaxas Yannis, Zaman Khalil, Michielin Olivier, Mach Nicolas, Bettini Adrienne, Schmitt Andreas M, Cantoni Nathan, Caspar Clemens B, Stettler Sonja, Malval Roma, Pless Miklos, Britschgi Christian, Renner Christoph, Koeberle Dieter, Schulz Jessica D, Kopp Christoph, Hayoz Stefanie, Stathis Anastasios, von Moos Roger, Swiss Group for Clinical Cancer Research (SAKK)
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribi K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. J Geriatr Oncol 2018; 10:304-310.
14.12.2018Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
14.12.2018J Geriatr Oncol 2018; 10:304-310
Kienle Dirk L, Andrieu Christiane, Bernhard Juerg, Lugli Alessandro, Baertschi Daniela, Helbling Daniel, Saletti Piercarlo, Kueng Marc, Bastian Sara, Horber Daniel, Koeberle Dieter, Winterhalder Ralph C, Quagliata Luca, Wicki Andreas, Ribi Karin, Dietrich Daniel, von Moos Roger
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). Eur J Cancer 2017; 89:82-89.
11.12.2017Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
11.12.2017Eur J Cancer 2017; 89:82-89
von Moos Roger, Plasswilm Ludwig, Zwahlen Daniel, Meier Urs R, Yan Pu, Izzo Paola, Klingbiel Dirk, Bärtschi Daniela, Zaugg Kathrin, Saletti Piercarlo, Rauch Daniel, Koeberle Dieter, Schacher Sabina, Hayoz Stefanie, Winterhalder Ralph C, Roth Arnaud, Bodoky György, Samaras Panagiotis, Berger Martin D, Swiss Group for Clinical Cancer Research (SAKK)
Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients
Fehr M, Müller J, Knitel M, Fornaro J, Horber D, Koeberle D, Cerny T, Gueller U. Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. Clin Colorectal Cancer 2017
21.03.2017Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients
21.03.2017Clin Colorectal Cancer 2017
Fehr Martin, Müller Joachim, Knitel Meinhard, Fornaro Jürgen, Horber Daniel, Koeberle Dieter, Cerny Thomas, Gueller Ulrich
Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients
Zumstein V, Vinzens F, Zettl A, Heinimann K, Koeberle D, von Flüe M, Bolli M. Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients. Swiss Med Wkly 2016; 146:w14315.
06.05.2016Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients
06.05.2016Swiss Med Wkly 2016; 146:w14315
Zumstein Valentin, Vinzens Fabrizio, Zettl Andreas, Heinimann Karl, Koeberle Dieter, von Flüe Markus, Bolli Martin
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015; 10:1451-7.
01.10.2015Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
01.10.2015J Thorac Oncol 2015; 10:1451-7
Gautschi Oliver, Kerjouan Mallorie, Michels Sebastian, Pall Georg, Rothschild Sacha, Schmid-Bindert Gerald, Scheffler Matthias, Veillon Rémi, Wannesson Luciano, Diebold Joachim, Zalcman Gérard, Filleron Thomas, Huret Benjamin, Curioni-Fontecedro Alessandra, Milia Julie, Cabarrou Bastien, Bluthgen Marie-Virginia, Besse Benjamin, Smit Egbert F, Wolf Juergen, Peters Solange, Früh Martin, Koeberle Dieter, Oulkhouir Youssouf, Schuler Martin, Mazières Julien
Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer
Blum D, Rosa D, deWolf-Linder S, Hayoz S, Ribi K, Koeberle D, Strasser F. Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer. J Pain Symptom Manage 2014; 48:1160-7.
23.05.2014Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer
23.05.2014J Pain Symptom Manage 2014; 48:1160-7
Blum David, Rosa Daniel, deWolf-Linder Susanne, Hayoz Stefanie, Ribi Karin, Koeberle Dieter, Strasser Florian
Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008
Worni M, Gueller U, White R, Castleberry A, Pietrobon R, Cerny T, Gloor B, Koeberle D. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas 2013; 42:1157-63.
01.10.2013Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008
01.10.2013Pancreas 2013; 42:1157-63
Worni Mathias, Gueller Ulrich, White Rebekah R, Castleberry Anthony W, Pietrobon Ricardo, Cerny Thomas, Gloor Beat, Koeberle Dieter
Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer
Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D. Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. Support Care Cancer 2013; 21:3085-93.
05.07.2013Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer
05.07.2013Support Care Cancer 2013; 21:3085-93
Hitz Felicitas, Ribi Karin, Li Qiyu, Klingbiel Dirk, Cerny Thomas, Koeberle Dieter
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research
Koeberle D, Herrmann R, Mora O, Ruhstaller T, Strasser F, Beretta K, Mingrone W, Caspar C, Dietrich D, Gerber D, Borner M, Saletti P, Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3702-8.
01.08.2008Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research
01.08.2008Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3702-8
Koeberle Dieter, Herrmann Richard, Mora Oreste, Ruhstaller Thomas, Strasser Florian, Beretta Kurt, Mingrone Walter, Caspar Clemens B, Dietrich Daniel, Gerber Daniela, Borner Markus, Saletti Piercarlo, Swiss Group for Clinical Cancer Research
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tàmas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701.
01.08.2008Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
01.08.2008Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701
Bernhard Jürg, Pestalozzi Bernhard C, Köhne Claus-Henning, Mingrone Walter, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Koeberle Dieter, Herrmann Richard, Figer Arie, Bauer Jean, Saletti Piercarlo, Dietrich Daniel, Scheithauer Werner, Gerber Daniela, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Central European Cooperative Oncology Group
Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?
Ruhstaller T, Mueller A, Koeberle D, Thuerlimann B. Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:8547-8.
20.11.2005Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?
20.11.2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:8547-8
Ruhstaller Thomas, Mueller Andreas, Koeberle Dieter, Thuerlimann Beat